NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NBY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nby · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for NovaBay Pharmaceuticals, Inc. (NBY) measures how much investors pay for each dollar of the company's trailing earnings. NBY's current PE ratio of 0.06x is calculated by dividing its stock price of $1.47 by its TTM earnings per share of $20.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NovaBay Pharmaceuticals, Inc.You NBY | $39M | 0.06x | — | $20.09 |
 Addex Therapeutics Ltd ADXN | $5M | N/A | — | -$7.20 |
 Impact BioMedical Inc. IBO | $7M | N/A | — | -$0.38 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 Matinas BioPharma Holdings, Inc. MTNB | $4M | N/A | — | -$1.89 |
 PharmaCyte Biotech, Inc. PMCB | $5M | 0.30x | — | $4.18 |
 Quoin Pharmaceuticals, Ltd. QNRX | $3M | N/A | — | -$10.55 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.80 | — | |
2024-12-31 FY2024 | — | $-0.43 | — | |
2023-12-31 FY2023 | — | $-16.07 | — | |
2022-12-31 FY2022 | — | $-70.72 | — | |
2021-12-31 FY2021 | — | $-36.82 | — | |
2020-12-31 FY2020 | — | $-77.11 | — | |
2019-12-31 FY2019 | — | $-118.73 | — | |
2018-12-31 FY2018 | — | $-112.84 | — | |
2017-12-31 FY2017 | — | $-118.36 | — | |
2016-12-31 FY2016 | — | $-211.74 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NovaBay Pharmaceuticals, Inc. (NBY) measures how much investors pay for each dollar of the company's trailing earnings. NBY's current PE ratio of 0.06x is calculated by dividing its stock price of $1.47 by its TTM earnings per share of $20.09.
Frequently asked questions
NBY pe ratio · 6 questionsNBY's current PE ratio is 0.06x as of 2026-06-08, based on a stock price of $1.47 and TTM EPS of $20.09. Data sourced from Financial Modeling Prep via NBY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NovaBay Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08